Abstracts tagged "Adalimumab"

Abstract Number: 488 • 2013 ACR/ARHP Annual Meeting
The Effect Of Methotrexate On Adalimumab Pharmacokinetics: Pooled Analysis Of Adalimumab Pharmacokinetics In Patients With Rheumatoid Arthritis After Subcutaneous Administration
Walid Awni¹, Sabine Pilari², Ghada Ahmed³ and Peter Noertersheuser², ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ³AbbVie, North Chicago, IL
Background/Purpose: Co-administration of methotrexate (MTX) has a significant effect on the pharmacokinetics (PK) of adalimumab (ADAL). MTX may impact the PK of other drugs by…
Abstract Number: 1383 • 2012 ACR/ARHP Annual Meeting
The Burden of Ankylosing Spondylitis and the Cost-Effectiveness of Anti-Tumor Necrosis Factor α Agents in Romania
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Ankylosing Spondylitis (AS) usually affects young males, severely impairing their quality of life. Chronic treatment of AS using anti-TNF α agents is costly and…
Abstract Number: 373 • 2012 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Early Rheumatoid Arthritis Patients Failing to Achieve Stable Low Disease Activity: Comparing Addition of Adalimumab to Methotrexate Monotherapy with Maintenance On Adalimumab Plus Methotrexate
Arthur Kavanaugh¹, Ronald F. van Vollenhoven², Paul Emery³, James W. Shaw⁴, Mary A. Cifaldi⁵, Stefan Florentinus⁶ and Josef S. Smolen⁷, ¹UCSD School of Medicine, La Jolla, CA, ²Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁴Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ⁵Abbott Laboratories, Abbott Park, IL, ⁶AbbVie, Rungis, France, ⁷Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Treat-to-target guidelines for rheumatoid arthritis (RA) suggest adjusting therapy every 3-6 months for pts who fail to achieve a disease activity target. However, pts…
Abstract Number: 1340 • 2012 ACR/ARHP Annual Meeting
Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Roy Fleischmann¹, Michael H. Schiff², Michael E. Weinblatt³, Michael A. Maldonado⁴, Elena M. Massarotti⁵ and Yusuf Yazici⁶, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Rheumatology Division, University of Colorado, Denver, CO, ³Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁴Medical Strategy, Bristol-Myers Squibb, Princeton, NJ, ⁵Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶New York University, New York, NY
Background/Purpose: Advancements in the understanding of Rheumatoid Arthritis (RA) have led to the development of novel therapeutics and treatment guidelines that target remission as an…
Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Vernon F. Schabert¹, Crystal Watson², George Joseph², Paige Iversen¹, Chakkarin Burudpakdee¹ and David J. Harrison², ¹IMS Health, Alexandria, VA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…
Abstract Number: 1303 • 2012 ACR/ARHP Annual Meeting
Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone
Edward Keystone¹, Ferdinand C. Breedveld², Désirée van der Heijde³, Ronald F. van Vollenhoven⁴, Stefan Florentinus⁵, Freddy Faccin⁶, Shufang Liu⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹University of Toronto, Professor of Medicine, Toronto, ON, Canada, ²Dept of Rheumatology C1R, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Karolinska Institute, Stockholm, Sweden, ⁵AbbVie, Rungis, France, ⁶Abbott, Abbott Park, IL, ⁷Immunology Development, Abbott, Abbott Park, IL, ⁸Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁹UCSD School of Medicine, La Jolla, CA
Background/Purpose: Effective treatment of rheumatoid arthritis (RA) patients (pts) aims to suppress inflammation, preserve physical function, and prevent structural damage, which together represent the hallmarks…
Abstract Number: 369 • 2012 ACR/ARHP Annual Meeting
Differences in Short-Term Radiographic Progression Following Early Response to Adalimumab Plus Methotrexate Vs. Methotrexate Alone
Ronald F. van Vollenhoven¹, James W. Shaw², Mary A. Cifaldi³, James Signorovitch⁴, Eric Q. Wu⁴, Thomas Samuelson⁴, Elizabeth Faust⁴ and Paul Emery⁵, ¹Karolinska Institute, Stockholm, Sweden, ²Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ³Abbott Laboratories, Abbott Park, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: To prevent disease progression, treat-to-target recommendations for rheumatoid arthritis (RA) include the evaluation and adjustment of drug therapy at least every 3 months until…
Abstract Number: 1304 • 2012 ACR/ARHP Annual Meeting
Long-Term Use of Adalimumab As Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate
Edward Keystone¹, Ferdinand C. Breedveld², Hartmut Kupper³, Shufang Liu⁴ and Stefan Florentinus⁵, ¹University of Toronto, Professor of Medicine, Toronto, ON, Canada, ²Leiden University Medical Center, Leiden, Netherlands, ³Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁴Immunology Development, Abbott, Abbott Park, IL, ⁵AbbVie, Rungis, France
Background/Purpose: There has been increased interest in understanding whether biologics can be safely withdrawn from patients (pts) receiving combination therapy with MTX once a clinical…
Abstract Number: 185 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet’s Disease with Uveitis As Main Involvement
M. Victoria Hernández¹, Marina Mesquida², Gerard Espinosa³, Victor Llorens², Laura Pelegrin², Juan D. Cañete⁴, Ricard Cervera⁵, Alfredo M. Adan² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ³Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁵Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: To assess the long-term efficacy and safety of tumour necrosis factor (TNF) antagonists (infliximab [IFX], adalimumab [ADA] and golimumab) for the treatment of patients…
Abstract Number: 2598 • 2012 ACR/ARHP Annual Meeting
Anti-Drug Antibodies Are Associated with Diminished Drug Levels and Treatment Failure
Miha Kosmac¹, Natasa Toplak², Gabriele Simonini³, Ilaria Pagnini⁴, Rolando Cimaz⁵, Vladka Curin Serbec¹ and Tadej Avcin⁵, ¹Research and Development Unit, Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia, ²Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital Ljubljana Slovenia, Ljubljana, Slovenia, ³Rheumatology Unit-Department of Paediatrics, A. Meyer Children's Hospital, Florence, Italy, ⁴Rheumatoloy Unit, Anna Meyer Children's Hospital, Department of Pediatrics, University of Florence, Florence, Italy, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Due to their proteinaceus character biologics can often induce an unwanted immune response that results in the formation of anti-drug antibodies in patients receiving…
Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Chad Pool¹, Gopi Shankar², Allen Schantz², George Gunn², Rebecca Bolce³, Marjatta Leirisalo-Repo⁴, Jim Wang¹, John A. Goldman⁵, Raphael J. DeHoratius⁶, Roy Fleischmann⁷ and Dennis Decktor⁶, ¹Janssen Services, LLC, Horsham, PA, ²Janssen R&D, LLC, PA, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Medical Quarters #293, Atlanta, GA, ⁶Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁷Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…
Abstract Number: 5 • 2012 ACR/ARHP Annual Meeting
Adalimumab Inhibits TNF-Enhanced Human Osteoclast Development More Effectively Than Other Biologic Agents Under in Vitro Conditions of Chronic TNF Exposure
Bohdan P. Harvey¹ and Zehra Kaymakcalan², ¹Biologics, Abbott Laboratories, Worcester, MA, ²Biologics, Abbott, Worcester, MA
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …
Abstract Number: 2466 • 2012 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: The OTIS Autoimmune Diseases in Pregnancy Project
Christina D. Chambers¹, Diana L. Johnson², Yunjun Luo¹, Janina L. Jimenez¹, Nicole Mirrasoul¹, Elizabeth Salas¹, Kenneth Lyons Jones² and OTIS Research Group³, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Pediatrics, La Jolla
Background/Purpose: The fully human, anti-tumor necrosis factor monoclonal antibody, adalimumab (ADA), is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile…
Abstract Number: 1242 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis
Mike Nurmohamed¹, Yanjun Bao², James Signorovitch³, Parvez M. Mulani⁴ and Daniel Furst⁵, ¹VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands, ²AbbVie, North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Abbott Laboratories, Abbott Park, IL, ⁵Div of Rheumatology, UCLA Medical School, Los Angeles, CA
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risks for cardiovascular (CV) comorbidities because of an increased prevalence of traditional CV risk factors and the…
Abstract Number: 2463 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis
Josh J. Carlson¹, Sarika Ogale², Fred Dejonckheere³ and Sean Sullivan⁴, ¹Pharmacy, University of Washington, Seattle, WA, ²Genentech, South San Francisco, CA, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Health Sciences Building, University of Washington, Seattle, WA
Background/Purpose: The ADACTA trial found that biologic naïve patients with severe active RA who are methotrexate (MTX) intolerant or in whom continued MTX treatment is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].